Xbrane Biopharma AB

XBRANE · Nasdaq Stockholm · Sweden

Public Market Listing

XBRANENasdaq Stockholm

Nasdaq Stockholm primary exchange listing

Live quotes, historical charts, and market capitalization for Xbrane Biopharma AB are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026FDA action dateRanibizumab (Ximluci)BsUFA action date for the Ximluci ranibizumab biosimilar BLA (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗
3 June 2026Filing acceptedRanibizumab (Ximluci)FDA accepts the resubmitted BLA for the Ximluci ranibizumab biosimilar (Xbrane)
US, FDA · Xbrane Biopharma; Valorum Biologics · Source ↗

Financial reports

No financial reports recorded.